SDG 3. GOOD HEALTH & WELL-BEING DRUG DISCOVERY Exscientia

Exscientia, University of Oxford partner to develop medicines targeting neuroinflammation to treat Alzheimer’s disease

Exscientia, a leading AI drug discovery company, has announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK─ODDI) to develop medicines targeting






Read more on www.PharmaBiz.com

You may also like

Comments are closed.